Toshifumi, "Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer" (2017). Open Access Articles. 3089.
Introduction
HER2, a member of the human epidermal growth factor receptor (HER) family, is a plasma membrane protein with intrinsic tyrosine kinase activity [1] . In contrast to other HER family members, HER2 is a receptor with no ligand; HER2 protein activation depends directly on its dimerization with another HER2 monomer or with a monomer of another HER family member, such as HER3 [2, 3] . After dimerization, the most important signaling pathways, such as the mitogen-activated protein kinase (MAPK) and PI3K pathways, are activated by HER2, resulting in cell duplication and regulation of apoptosis [4] . HER2 signal transduction can be dysregulated via different mechanisms. HER2 overexpression, generally resulting from HER2 gene amplification [5, 6] , is one of the main causes of the constitutive activation of HER2 signal transduction in many cancers [7] . HER2 overexpression and/or amplification are associated with carcinogenesis, poor prognosis, and may also predict the response to chemotherapy [7] . Under the rationale for using anti-HER2 targeted approaches to block its oncogenic effects, anti-HER2 monoclonal antibodies have been designed for HER2-positive tumors. Trastuzumab is a monoclonal antibody that recognizes the extracellular portion of the HER2 receptor, and once bound, it completely inhibits HER2 activity [8] . Today, trastuzumab treatment is the standard care for HER2-positive breast [9] and gastric cancers [10] . In addition to breast and gastric cancers, preclinical models and clinical trials are underway to assess the efficacy of HER2-targeted therapy for patients with colorectal cancer (CRC) [11] . Several studies reported the incidence of HER2-positive cases and its clinical significance in CRC [12] [13] [14] [15] [16] [17] [18] [19] , and the use of trastuzumab for HER2-positive cases is recognized as a promising treatment strategy for A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT 6 KRAS wild-type metastatic CRC [19] [20] [21] . Recently, the HERACLES trial demonstrated the efficacy of dual-targeted therapy with trastuzumab and lapatinib for KRAS codon 12/13 wildtype and HER2-positive CRC [22] . Hence, both KRAS mutation and HER2 status should be evaluated to select candidates for HER2-targeted therapy in CRC.
In current histopathology, the HER2 status of breast and gastric cancer is determined by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) [23, 24] ; likewise, the HER2 status of CRC is usually evaluated by IHC and FISH [22] . Conversely, by utilizing next-generation sequencing technology, projects such as The Cancer Genome Atlas (TCGA) have profiled genomic changes in several cancers including CRC [25] . Comprehensive genomic sequencing (CGS) can detect gene mutations and copy number alterations in a single assay, including KRAS mutation and HER2 amplification. However, it is not clear whether CGS has the same diagnostic value as IHC and FISH for detecting HER2-positive CRC. Therefore, the aim of this study was to clarify the utility of CGS for detecting HER2positive CRC.
Materials and methods

Patients
A total of 201 patients diagnosed with stage I -IV CRC according to AJCC 7 th edition [26] who performed primary tumor resection between 2009 and 2015 at Niigata University 
Pathological evaluation of HER2 status
Resected specimens were fixed immediately in 10% buffered formalin for 24 h, and the entire tumor was cut into step-wise sections and embedded in paraffin. Each section was examined with hematoxylin and eosin (HE) staining, and the archives were reviewed for each case to select one cross-section with the most invasion. The corresponding paraffin blocks were recut, making 4-m thick slices, and 3 serial sections were assigned for HE staining, anti-HER2 staining, and a negative control. HER2 status was determined according to the HERACLES diagnostic criteria: HER2-positive status was defined as tumors with a 3+ HER2 score in more than 50% of cells by IHC or with a 2+ HER2 score and a HER2:CEP17 ratio higher than 2.0 in more than 50% of cells by FISH [22] .
IHC for evaluating HER2 status
Specimen slides were deparaffinized, followed by dehydration with ethanol. The sections were washed 3 times with phosphate-buffered saline for 5 min. The sections were digested with 0.03 U/g protease, diluted with 0.05 M Tris-HCl pH 7.6, at room temperature for 5 min Inc.) at room temperature for 30 min, followed by incubation for 10 min with a DAB kit (Nichirei Biosciences, Inc.), and the sections were counterstained with hematoxylin. Positive tissue controls were included in each run; these tissues were breast tumors with known HER2 protein overexpression and HER2 gene amplification [27] .
FISH for evaluating HER2 status
Specimen slides were deparaffinized, followed by dehydration with ethanol. Each slide was treated with a Vysis Paraffin Pretreatment Kit (Abbott Molecular, Des Plaines, IL). After pretreatment, the resulting specimen DNA was denatured and the slides were dehydrated in serial ethanol solutions and subsequently allowed to hybridize with the PathVysion (Abbott Molecular) probe mixture. Following hybridization, excess and unbound probe was removed by a series of washes, and the chromosomes and nuclei were counterstained with the DNAspecific stain 4′,6 diamidino-2-phenylindole, which fluoresces blue under UV illumination.
Hybridization of the HER2/neu and CEP 17 DNA probes was viewed using a fluorescence microscope equipped with appropriate excitation and emission filters, allowing visualization of the orange and green fluorescent signals and the blue counterstained chromosomes and nuclei [28] .
CGS of primary sites
Archival tissue in the form of formalin-fixed, paraffin-embedded tumor or unstained tissue sections obtained during primary tumor resection were used for CGS, and HER2 amplification, HER2 mutation, and KRAS exon 2 (codon 12 and 13) mutation were evaluated.
An independent pathologist evaluated tumor content on HE-stained slides for each study sample to ensure >50% tumor content was present. Where applicable, unstained slides were macro-dissected to enrich for tumor content and DNA was extracted using a BioStic FFPE Microbiosystems, Tokyo, Japan).
HER2 status and other clinicopathological characteristics
Comparison of HER2 status between primary and paired metastatic sites
In the present study, 45 of the 201 patients underwent metastasectomy. The following metastatic sites were evaluated for HER2 status by the same methods as for the primary site [22] : liver (30 patients), lung (4 patients), ovary (3 patients), peritoneum (2 patients), brain (2 patients), omentum (2 patients), para-aortic lymph node (1 patient), and bone (1 patient).
Statistical analysis
Statistical analyses were performed with IBM SPSS Statistics 22 (IBM Japan, Inc., Tokyo, Japan). Fisher's exact test was used to evaluate the associations between HER2 status and HER2 amplification evaluated using CGS, and HER2 status and HER2 mutation evaluated using CGS. HER2 status and each clinicopathological variable, and HER2 status between the primary site and metastatic site was also evaluated by Fisher's exact test. P-values less than 0.05 were considered statistically significant.
Results
IHC and FISH for HER2 status at the primary site
Ten patients were HER2 IHC 3+ in more than 50% of the cancer area (Fig. 1A, B ), and 2 patients were HER2 IHC 3+ in less than 50% (Fig. 1C, D) . Fifteen patients were HER2 IHC 2+; however, there was no patient with IHC 2+ and a HER2:CEP17 ratio higher than 2.0 in more than 50% of cells by FISH. Hence, 10 of the 201 (5%) patients with HER2 IHC 3+ in more than 50% of the cancer area were diagnosed as HER2-positive by the HERACLES diagnostic criteria.
Association between HER2 status and HER2 amplification evaluated using CGS
CGS successfully detected alterations in 415 genes including KRAS codon 12/13 mutation and HER2 amplification. Forty-nine of the 201 (29%) patients had a KRAS codon 12/13 mutation. Ten of the 201 (5%) patients had a HER2 amplification. The result of HER2 amplification evaluated using CGS and that of HER2 status evaluated using IHC were completely identical in all 201 patients (P < 0.001) (Table 1) ( Table 2 ). Nine of the 10 HER2positive patients were KRAS 12/13 wild-type, who were considered to be possible candidates for HER2-targeted therapy (Fig. 2) .
Association between HER2 status and HER2 mutation evaluated using CGS
CGS also detected HER2 mutations (V308M, S310Y, R647K, R678Q, and A879delinsAE) in
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ACCEPTED MANUSCRIPT 12 6 of 201 (3%) patients. Among the 6 patients, only 1 patient had both HER2 mutation (S310Y) and HER2 amplification, and the patient showed HER2 positive (IHC 3+) ( Table 2 ).
No significant association was observed between HER2 status and HER2 mutation (P = 0.267).
HER2 status and other clinicopathological characteristics
There was no significant association between HER2 status and other clinicopathological characteristics ( Table 3) .
Comparison of HER2 status between the primary and paired metastatic sites
At the metastatic sites, 3 of 45 (7%) patients were HER2-positive. Comparing between the primary and metastatic sites, 44 of the 45 (98%) patients showed a concordant HER2 status (Table 4 ). Focusing on the 4 patients with a positive HER2 status at the primary site, 3 of these patients were HER2-positive at the metastatic site ( Fig. 3) ; however, the remaining patient was HER2-negative at the metastatic site: IHC score 3+ (100% area) at the primary site and IHC 0 at the metastatic site (para-aortic lymph node).
Discussion
In the present study, we showed two main results regarding the utility of CGS for detecting HER2-positive CRC patients. First, CGS successfully detected HER2 amplification in 10 of 201 (5%) patients. Second, the result for HER2 amplification evaluated using CGS and that for HER2 status evaluated using IHC and FISH were completely identical in all 201 patients.
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HER2-targeted therapy is considered a promising strategy for KRAS wild-type metastatic CRC [19] [20] [21] , and the evaluation of HER2 status and KRAS mutation is necessary to select candidates for HER2-targeted therapy. Recently, the HERACLES trial revealed the efficacy of dual targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic CRC [22] . In the trial, HER2 status was evaluated using IHC and FISH, and HER2-positivity was defined using the CRC-specific HERACLES diagnostic criteria [22] . In the present study, we also assessed HER2 status according to the HERACLES diagnostic criteria. Conversely, CGS can detect multiple gene alterations including KRAS codon 12/13 mutation and HER2 amplification in a single assay. However, to date, no study has investigated the concordance of HER2-positivity between HER2 status and HER2 amplification detected by CGS. In the current study, we tested the utility of CGS for detecting HER2-positive CRC using a 415-gene panel designed for solid tumors. Patients with any known KRAS or NRAS mutation should not be treated with EGFR-targeted therapy such as cetuximab and panitumumab [32] . In the present study, we successfully detected alterations in 415 genes including KRAS, NRAS, and BRAF mutations and HER2
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TCGA project found that 4% of CRC patients have HER2 mutations [25] . However, to date, HER2 mutations in CRC has not been fully studied, and it is an open question as to whether HER2 mutations are clinically important in CRC. Kavuri et al. reported that HER2 mutations S310F, L755S, V777L, V842I, and L866M are activating mutations in CRC, and the HER2 activating mutations may be drug targets for the treatment of CRC [33] . In the present study, we identified 6 of 201 (3%) patients with HER2 mutations (V308M, S310Y, R647K, R678Q, and A879delinsAE), that require further investigation to determine their oncogenicity.
Among the 6 patients with HER2 mutations, only 1 patient had both HER2 mutation and HER2 amplification, who interestingly showed HER2 positive (IHC3+). We speculate that patients with both HER2 mutation and HER2 amplification may be candidates for HER2targeted therapy when the patients show HER2 positive using IHC/FISH. In addition to HER2 amplification, future studies might have to focus on the significance of HER2 mutations in CRC, and clarify whether HER2 mutations are drug targets for CRC treatment.
In this study, we showed the utility of CGS for detecting HER2-positive patients, who are candidates for HER2-targeted therapy; however, HER2-positive patients do not always demonstrate a favorable response to this treatment approach. Discordant HER2 status between primary and metastatic sites is one possible reason underlying drug resistance to HER2-targeted therapy. In gastric cancer, previous reports revealed that discordant HER2
ACCEPTED MANUSCRIPT 15 status between primary and metastatic sites was observed in 5-20% of patients [34] . However, in CRC, this issue has not been investigated fully to date. In this study, we demonstrated that 1 of the 4 (25%) patients with HER2-positive status at the primary site was HER2-negative at the metastatic site, suggesting that HER2 status is not necessarily maintained during the metastatic process. In general, tissue samples from the metastatic site may not always be available. Future studies, such as targeted sequencing analysis of liquid biopsy samples might have the potential to resolve this issue and facilitate precision medicine [35] .
Regarding pros and cons of IHC/FISH and CGS for evaluating HER2 status, we consider that IHC/FISH are convenient, widely accepted, and established way to evaluate for breast and gastric cancer. However, diagnostic reproducibility may be sometimes problematic;
especially, because of tumor heterogeneity. Conversely, CGS is expensive compared to IHC/FISH, and tested in only specialized laboratories. However, CGS has ability to test numerous gene alterations, which are directly associated with treatment strategy, in a single assay. We believe that CGS has possibility to facilitate precision medicine.
This study has two potential limitations. First, this was a retrospective study performed at two institutions and included a small number of patients. Second, we could not demonstrate an association between HER2 amplification detected by CGS and the efficacy of HER2-targeted therapy. Future studies should investigate patients with metastatic CRC to determine whether HER2-targeted therapy is effective for patients with HER2 amplification detected by CGS.
Conclusion
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There is a small, distinct category of HER2-positive CRC patients who are candidates for HER2-targeted therapy. CGS has the same sensitivity as IHC and FISH for detecting HER2positive patients and has the potential to facilitate precision medicine and tailor-made treatment. Negative 0 -R678Q Abbreviations: HER2, human epidermal growth factor receptor 2; CGS, comprehensive genomic sequencing; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization. Abbreviations: HER2, human epidermal growth factor receptor 2. a Cut-off value = 10 lymphocytes/5 high power fields.
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